The long awaited TransCon PTH phase 3 will start soon!
TransCon PTH is an investigational long-acting prodrug in development as a potential once-daily replacement therapy for hypoparathyroidism. By providing PTH at physiologic levels for 24 hours a day, TransCon PTH is designed to normalize blood and urinary calcium levels, serum phosphate levels and bone turnover thus addressing both the short-term symptoms and long-term complications of hypoparathyroidism.
Ascendis Pharma has finished phase 1 with positive results, and now are completing phase 2. By the start of next year, they will be ready to start phase 3 which will involve many more patients with hypoparathyroidism who would like to participate. Please stay tuned to either our website or the Ascendis Pharma website for more information.
This information is provided for educational purposes only. It should not be used for diagnostic or treatment purposes. If you wish to obtain more information about this disorder, please contact your personal physician.